In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
In the latest session, Amneal Pharmaceuticals Inc (NASDAQ: AMRX) closed at $9.53 up 1.28% from its previous closing price of $9.41. In other words, the price has increased by $1.28 from its previous closing price. On the day, 1.26 million shares were traded. AMRX stock price reached its highest trading level at $9.6158 during the session, while it also had its lowest trading level at $9.39.
Ratios:
For a deeper understanding of Amneal Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 36.87 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.05. For the most recent quarter (mrq), Quick Ratio is recorded 0.88 and its Current Ratio is at 1.43.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on June 06, 2025, initiated with a Buy rating and assigned the stock a target price of $12.
On February 24, 2025, JP Morgan Upgraded its rating to Overweight which previously was Neutral and also upped its target price recommendation from $9 to $12.
JP Morgan Upgraded its Underweight to Neutral on September 06, 2024, while the target price for the stock was maintained at $9.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 20 ’25 when BOYER ANDREW S bought 175,000 shares for $9.36 per share.
BOYER ANDREW S bought 104,244 shares of AMRX for $969,469 on Aug 20 ’25. On Aug 14 ’25, another insider, Shah Nikita, who serves as the Executive Vice President of the company, sold 71,694 shares for $9.29 each. As a result, the insider received 666,037 and left with 267,235 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMRX now has a Market Capitalization of 2993172736 and an Enterprise Value of 5565173760. As of this moment, Amneal’s Price-to-Earnings (P/E) ratio for their current fiscal year is 1489.06, and their Forward P/E ratio for the next fiscal year is 10.55. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 63.55. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.05. Its current Enterprise Value per Revenue stands at 1.951 whereas that against EBITDA is 8.902.
Stock Price History:
The Beta on a monthly basis for AMRX is 1.18, which has changed by 0.13723147 over the last 52 weeks, in comparison to a change of 0.13054323 over the same period for the S&P500. Over the past 52 weeks, AMRX has reached a high of $9.59, while it has fallen to a 52-week low of $6.68. The 50-Day Moving Average of the stock is 14.52%, while the 200-Day Moving Average is calculated to be 17.59%.
Shares Statistics:
For the past three months, AMRX has traded an average of 1.63M shares per day and 1865350 over the past ten days. A total of 314.04M shares are outstanding, with a floating share count of 144.70M. Insiders hold about 53.93% of the company’s shares, while institutions hold 41.91% stake in the company. Shares short for AMRX as of 1753920000 were 4926716 with a Short Ratio of 3.03, compared to 1751241600 on 6552241. Therefore, it implies a Short% of Shares Outstanding of 4926716 and a Short% of Float of 2.4400001000000002.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The performance of Amneal Pharmaceuticals Inc (AMRX) in the stock market is under the watchful eye of 4.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is $0.16, with high estimates of $0.17 and low estimates of $0.14.
Analysts are recommending an EPS of between $0.78 and $0.74 for the fiscal current year, implying an average EPS of $0.77. EPS for the following year is $0.9, with 4.0 analysts recommending between $0.93 and $0.88.
Revenue Estimates
A total of 4 analysts believe the company’s revenue will be $768.1M this quarter.It ranges from a high estimate of $772.45M to a low estimate of $760.94M. As of the current estimate, Amneal Pharmaceuticals Inc’s year-ago sales were $702.47MFor the next quarter, 4 analysts are estimating revenue of $812.88M. There is a high estimate of $826.9M for the next quarter, whereas the lowest estimate is $792.41M.
A total of 4 analysts have provided revenue estimates for AMRX’s current fiscal year. The highest revenue estimate was $3.01B, while the lowest revenue estimate was $2.97B, resulting in an average revenue estimate of $3B. In the same quarter a year ago, actual revenue was $2.79BBased on 4 analysts’ estimates, the company’s revenue will be $3.19B in the next fiscal year. The high estimate is $3.22B and the low estimate is $3.14B.
